Irina Rivkind Comments: What Analysts Think About Valeant Pharmaceuticals Intl Inc’s Increased 2015 Guidance

 January 13, 2015, ValueWalk

In a report published by, analyst Irina Rivkind of Cantor Fitzgerald reiterated a Buy rating on Valeant with a price target of $184 on January 9th. Rivkind responded to the increased guidance announced on the conference called, attributing it to “strong launches, which are expected to contribute over $550-700M, and the addition of $160M in sales from the 4Q:14 Marathon hospital specialty wwwucts portfolio acquisition, offset by approximately $200M in generic impact (mostly in 2H:15) and $300M in negative FX (with a negative $0.47 EPS impact). Valeant also expects to deliver 4Q:14 EPS at the top of its prior guided range (>$2.55).” Rivkind continued that she is impressed by “the CEO’s commitment to the business (moving to 100% stock compensation), the sheer size of the 2016 pipeline (8 potential launches), and the double-digit organic growth of the business.” 

Irina Rivkind has rated Valeant 7 times since March of 2014 with a 86% success rate recommending the company and a +16.8% average return per Valeant recommendation. Overall, she has a 67% success rate recommending stocks with a +19.3% average return per recommendation.